Maintenance of clinical response and consistent safety profile with up to three years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials.
暂无分享，去创建一个
A. Kimball | A. Armstrong | K. Papp | K. Reich | P. Foley | Chenglong Han | K. Gordon | A. Blauvelt | C. Griffiths | Shu Li | B. Randazzo | Michael Song | Yaung-Kaung Shen